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Treating Pulmonary 
Arteriovenous 
Malformations 
P
ulmonary arteriovenous malformations (AVMs) 
represent direct connections between the pul-
monary artery and vein. Although they can be 
sporadic, approximately 70% of pulmonary AVMs 
are associated with hereditary hemorrhagic telangiectasia 
(HHT).1 If left untreated, patients can present with para-
doxical embolization (stroke or brain abscess), dyspnea 
and exercise intolerance, or pulmonary hemorrhage.2 
Embolization has become the favored method of treat-
ment. This article serves to provide recommendations 
of what and what not to do in patients with pulmonary 
AVMs, based partially on published literature and par-
tially on our personal experience in treating a multitude 
of these technically challenging lesions.
WHAT TO DO
Screen for HHT
Any patient with a pulmonary AVM has a high likeli-
hood of HHT, and the presence of multiple pulmonary 
AVMs is almost pathognomonic of HHT. Ask any patient 
with pulmonary AVM the following two questions and 
perform the following examination: 
• Do you have nosebleeds? More than 95% of adult 
patients with HHT have spontaneous and recurrent 
nosebleeds (median age of onset, 12 years).
• Do any of your family members get frequent nose-
bleeds? Because HHT is autosomal dominant (it does 
not skip generations), either the patient’s mother or 
father is usually affected, and often other family mem-
bers are as well.
Examine the lips, tongue, oral mucosa, and fingertips 
for small red spots. Telangiectasias are present in > 90% 
of adult patients with HHT, usually beginning in their 20s 
and increasing with age.
If any one of the three examination findings is posi-
tive, HHT is possible/probable, and if any two or three are 
positive, the diagnosis of HHT is definite, given that they 
already have a pulmonary AVM. In this case, referral to the 
closest HHT Center of Excellence (there are 22 in North 
America and several in Europe) should be considered.
Think Before You Treat
Historically, a feeding artery diameter of 3 mm was con-
sidered to trigger embolization therapy for a pulmonary 
AVM.2 Due to advancements in techniques and catheter 
technology, we now have the capability to treat lesions 
with feeding arteries as small as 1 mm. However, not all 
of these small AVMs require treatment. Complications 
of pulmonary AVMs < 2 mm are almost unheard of, and 
complications from AVMs in the 2- to 3-mm size range are 
uncommon.3 Treating asymptomatic AVMs with a feeding 
artery of at least 3 mm is widely supported, as well as any 
symptomatic AVM. Asymptomatic AVMs under 2 mm are 
considered very low risk and are not typically treated. For 
asymptomatic 2- to 3-mm AVMs, embolization is generally 
recommended, but we often defer treatment in children 
and adolescents (with the plan to embolize at age 18), and 
in elderly patients.
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Finding the Treasure Is Easiest With a Map
The procedure should commence with a high-volume 
angiographic run from the right or left pulmonary artery 
through a pigtail catheter. The ideal angle is determined 
by review of the preprocedure CT scan; if in doubt, a 
30° to 40° contralateral oblique view opens and sepa-
rates the pulmonary arteries most effectively. The best 
sensitivity for detecting pulmonary AVMs will come 
with imaging in full inspiration; however, this run will be 
almost useless as a “smart mask” for actual guidance into 
the target vessel. For intraprocedural guidance into the 
AVM itself, it is often more useful to ask the patient to 
“stop breathing” rather than to “take a breath in.”
Have the Right Stuff
Pulmonary AVM embolization is technically challeng-
ing because the constant movement of the heart and 
lungs tends to dislodge carefully placed catheters; wires 
tend to select the branch you do not want; and fear 
(or anxiety) is common at the moment of coil or plug 
release. For stability, we use a White Lumax catheter 
set (Cook Medical), which consists of a long, 7-F angled 
guide catheter to maintain stability in the parent artery 
and an inner 5-F angiographic catheter for vessel selec-
tion. If the origin of the desired vessel is particularly 
tortuous or difficult, a 5-F angled Glidecath (Terumo 
Interventional Systems) can be helpful. A Judkins 
Right-4 catheter (Merit Medical Systems, Inc.) is par-
ticularly effective for acute angled origins of the upper 
or middle lobes (Figure 1). It is preferable to navigate 
the angiographic catheter into the desired vessel using 
careful rotation and advancement of the catheter itself, 
checking the course with puffs of contrast. If this fails, 
an angled Glidewire (Terumo Interventional Systems) 
can be used to select the desired vessel, being careful 
not to push too aggressively. 
Get Yourself Out There
Due to potential collateralization, AVM recanali-
zation is common if embolization is performed too 
proximally. Distal embolization, either at the very 
distal aspect of the feeding artery4 or within the AVM 
itself5 is desired to minimize recurrence of the lesion. 
In AVMs with a large feeding artery, this can often 
be accomplished using Amplatzer Vascular Plugs (St. 
Jude Medical, Inc.) delivered through the 7-F guide 
catheter. These are typically oversized by 30% to 50%, 
with respect to the target vessel diameter. For inter-
mediate-size AVMs, 0.035-inch coils can be delivered 
Figure 1.  This figure shows a 45-year-old man with HHT and asymptomatic 3-mm left upper lobe pulmonary AVM detected 
on routine screening. A left upper lobe angiogram demonstrates the AVM (A). Access to the left upper lobe artery was dif-
ficult, requiring a Judkins Right-4–shaped catheter. An angiogram through a 0.021-inch microcatheter demonstrates appro-
priate position at the proximal margin of the aneurysmal sac (B). Spot film demonstrating appropriate position of a MVP-3Q, 
prior to deployment (C). Final angiography confirms complete occlusion of the AVM with a single device (D). 
Figure 2.  This figure shows a 39-year-old man with HHT, 
after coil embolization of left lower lobe pulmonary 
AVM 5 years earlier. Initial angiography demonstrates 
recanalization through the previously placed coils (A). After 
deployment of a single MVP-5Q, the recanalized vessel is 
completely occluded (B). The adjacent pulmonary artery 
branches are spared.
A
A
B
B
C D
54 ENDOVASCULAR TODAY APRIL 2016 VOL. 15, NO. 4
EMBOL I ZAT ION
through a 4- or 5-F catheter, an Amplatzer Vascular 
Plug 4 can be delivered through a 5-F angiographic 
catheter, and MVP-7Q and MVP-9Q microvascular 
plugs (Medtronic) can be delivered through 4- and 5-F 
catheters, respectively. For small or tortuous AVMs, 
distal embolization usually requires a microcatheter. It 
is important to use a microcatheter size that is com-
patible with your desired embolic agent (a standard 
microcatheter for standard microcoils or a high-flow 
microcatheter for larger microcoils). Try to avoid 
smaller microcatheters, which provide suboptimal 
angiographic runs and can be easily misdirected into 
tiny pulmonary sub-branches. 
We have found the MVP-3Q and MVP-5Q to be very 
useful for single-device occlusion of small AVMs. The 
MVP-3Q occludes vessels up to 3 mm and is compat-
ible with standard-size microcatheters, whereas the 
MVP-5Q occludes vessels up to 5 mm and is compatible 
with high-flow microcatheters. For complex AVMs, long 
detachable coils can be used to embolize the AVM 
nidus to prevent recanalization (Figure 2). We have 
found that the standard and soft Interlock fibered 
coils (Boston Scientific Corporation) provide a good 
balance of rapid deployment, efficient occlusion, and 
relatively low cost. Concerto coils (Medtronic) are 
very soft, reducing pushback and making them use-
ful when the microcatheter is tenuously positioned. 
Other good detachable coil alternatives include Ruby 
coils (Penumbra, Inc.) and Azur hydrocoils (Terumo 
Interventional Systems). For pushable coils, the Nester 
and MicroNester line of coils (Cook Medical) provide 
inexpensive cross-sectional occlusion.
Beware the Air (and the Clot)
An air embolism is a serious risk when treating pul-
monary AVMs; any air passing into a pulmonary AVM 
can pass directly into the left-sided circulation and from 
there, into the brain, causing a transient ischemic attack 
or worse. Prior to the procedure, nurses should be cau-
tioned not to inject any air bubbles when the IV is started, 
and an air filter should be placed if available. During the 
procedure, blood should be aspirated prior to each injec-
tion, even with the microcatheter, to ensure a solid liquid 
column within the catheter. Wires should be removed 
either under saline within a basin or with a constant drip 
of saline into the catheter hub. Although there is institu-
tional variation, we choose to administer heparin to all 
patients immediately after venous access to prevent clot 
formation on the catheter during treatment.
WHAT NOT TO DO
Don’t Test Your Luck
The moment of delivery of the first coil is often one 
of consternation. To minimize the stress, use a long, 
detachable, and slightly oversized coil for the first coil, 
and watch that it deforms as you push it out (suggest-
ing ample wall contact) and that it is completely immo-
bile prior to full deployment (suggesting secure position). 
If there is any concern, simply recapture the coil and 
choose a more appropriate size. Pushable coils can be 
used behind the first coil, if desired, but the risk/reward 
ratio greatly favors that the all-important first coil be 
detachable. Alternatively, use a vascular plug, all of which 
are detachable and secure if sized properly (if you are 
unsure, use a larger size).
Figure 3.  This figure shows a 32-year-old woman with HHT and history of brain abscess. Initial pulmonary angiography con-
firms a complex AVM in the right lower lobe (A). Proximal embolization was considered to be high risk for recanalization. 
Control angiography after coiling of the distal portion of the anterior basilar segmental artery demonstrates persistent supply 
from the proximal portion (B). After coiling of this branch, angiography of the lateral basilar segmental artery demonstrates 
further supply to the AVM (C). Final angiography demonstrates complete occlusion of the AVM from its distal to proximal 
extent (D). A total of 36 coils were used. 
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Don’t Skimp on the Embolic Agent
Recanalization occurs either by collateralization 
around the embolic agent, or by flow resumption 
directly through the embolic agent. To minimize the lat-
ter, create a tight coil pack composed of multiple coils, 
and if in doubt, add more. If a porous plug, such as an 
Amplatzer Vascular Plug, is used, backing it up with one 
or two cheap pushable coils will help prevent recanali-
zation through the plug. Polytetrafluoroethylene-lined 
plugs, such as the MVP, can be a one-device solution 
(Figure 3), but may not produce full occlusion if placed 
in areas of tortuosity and can also be backed up with 
coils in this instance.
Don’t Sacrifice Safety for Convenience
Being sure not to sacrifice safety is especially impor-
tant when treating multiple lesions in one session 
because radiation and contrast limits may come into 
play. There is no shame in staging the procedure and 
bringing the patient back on a different occasion to fin-
ish the job.
CONCLUSION
Treatment of pulmonary AVMs is challenging and 
exhilarating. Proper planning and appropriate equip-
ment, along with good working knowledge of what 
(and what not) to do, will help optimize outcomes.  n
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